Timothy G. Murray
Research Subjects
Timothy G. Murray has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Aaron S. Gold
Miami Ocular Oncology and Retina, Miami, FL, USA
12 shared publicationsAzeema Latiff
Miami Ocular Oncology and Retina, Miami, FL, USA
12 shared publicationsVictor M. Villegas
Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico, USA
11 shared publications- Victor Manuel Villegas
Department of Ophthalmology, University of Puerto Rico School of Medicine, San Juan, PR 00936, USA
7 shared publications - Aaron S. Gold
Murray Ocular Oncology and Retina Miami Florida
6 shared publications Aaron Gold
Murray Ocular Oncology and Retina, Miami, FL, USA
4 shared publications
Latest Publications
- 19 May 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (6) , 1306-1310
Supraorbital Vibration as an Adjuvant to Topical Anesthesia During Intravitreal Therapy
Purpose: To evaluate the safety and efficacy of supraorbital vibration anesthesia in combination with topical anesthesia during intravitreal therapy. The primary objective is to assess the effectiveness of vibrational anesthesia in reducing pain and stress associated with the procedure. Methods: A retrospective chart review of 842 patients undergoing intravitreal therapy was conducted, with 834 patients opting for vibrational anesthesia. Additionally, a survey of 50 patients was conducted to evaluate the effects of vibrational anesthesia on patient experiences. Results: No adverse events were observed following intravitreal therapy in conjunction with vibrational anesthesia. Additionally, a survey of 50 patients revealed that 94% preferred vibrational anesthesia, and 84% would request it in future treatments. The majority of patients surveyed reported a reduction in pain (82%) and stress (72%) with the use of vibrations. Conclusions: The results suggest that supraorbital vibration anesthesia is safe and effective in reducing pain and stress during intravitreal therapy. Further studies are warranted to validate these findings and determine optimal device placement.
- 19 May 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (6) , 1306-1310
Supraorbital Vibration as an Adjuvant to Topical Anesthesia During Intravitreal Therapy
Purpose: To evaluate the safety and efficacy of supraorbital vibration anesthesia in combination with topical anesthesia during intravitreal therapy. The primary objective is to assess the effectiveness of vibrational anesthesia in reducing pain and stress associated with the procedure. Methods: A retrospective chart review of 842 patients undergoing intravitreal therapy was conducted, with 834 patients opting for vibrational anesthesia. Additionally, a survey of 50 patients was conducted to evaluate the effects of vibrational anesthesia on patient experiences. Results: No adverse events were observed following intravitreal therapy in conjunction with vibrational anesthesia. Additionally, a survey of 50 patients revealed that 94% preferred vibrational anesthesia, and 84% would request it in future treatments. The majority of patients surveyed reported a reduction in pain (82%) and stress (72%) with the use of vibrations. Conclusions: The results suggest that supraorbital vibration anesthesia is safe and effective in reducing pain and stress during intravitreal therapy. Further studies are warranted to validate these findings and determine optimal device placement.
- Open Access
- 9 October 2025
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 40, 102450
Brachytherapy for choroidal metastasis secondary to primary urethral adenocarcinoma of Müllerian origin: A case report
- 9 October 2025
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 40, 102450
Open AccessBrachytherapy for choroidal metastasis secondary to primary urethral adenocarcinoma of Müllerian origin: A case report
- Open Access
Update on Retinoblastoma Therapies
Retinoblastoma is a success story in pediatric oncology, evolving from life-saving interventions to approaches that preserve eyes and vision while minimizing complications. Initially managed with enucleation and radiotherapy, treatment now emphasizes eye preservation through chemotherapy as the cornerstone therapy. Various chemotherapy delivery methods—including intravenous (IVC), intraarterial (IAC), intravitreal, intracameral, and periocular—offer flexibility in treatment. Studies show nearly 100% eye salvage rates for groups A–C. For advanced cases (groups D and E), IAC has achieved outcomes that were not possible before. Intravitreal injections, when performed safely, may help avoid enucleation and radiotherapy in advanced cases, preserving vision, even in complex scenarios, with vitreous seeding. Each strategy may be tailored to tumor and patient characteristics that may help optimize outcomes. Recent innovations like liquid biopsy, prenatal diagnosis, prognostic biomarkers, and new surgical methods, such as tylectomy and chemoplaque, are paving the way for more personalized care. While advanced extraocular or metastatic retinoblastoma remains challenging, these advancements underscore a shift towards better outcomes and individualized management. The future holds promise for refining treatment strategies to maximize eye and vision preservation while ensuring patient survival.
Open AccessUpdate on Retinoblastoma Therapies
Retinoblastoma is a success story in pediatric oncology, evolving from life-saving interventions to approaches that preserve eyes and vision while minimizing complications. Initially managed with enucleation and radiotherapy, treatment now emphasizes eye preservation through chemotherapy as the cornerstone therapy. Various chemotherapy delivery methods—including intravenous (IVC), intraarterial (IAC), intravitreal, intracameral, and periocular—offer flexibility in treatment. Studies show nearly 100% eye salvage rates for groups A–C. For advanced cases (groups D and E), IAC has achieved outcomes that were not possible before. Intravitreal injections, when performed safely, may help avoid enucleation and radiotherapy in advanced cases, preserving vision, even in complex scenarios, with vitreous seeding. Each strategy may be tailored to tumor and patient characteristics that may help optimize outcomes. Recent innovations like liquid biopsy, prenatal diagnosis, prognostic biomarkers, and new surgical methods, such as tylectomy and chemoplaque, are paving the way for more personalized care. While advanced extraocular or metastatic retinoblastoma remains challenging, these advancements underscore a shift towards better outcomes and individualized management. The future holds promise for refining treatment strategies to maximize eye and vision preservation while ensuring patient survival.
- Open Access
Combined Cataract and Vitrectomy Surgery in Pediatric Patients
Purpose: To review the current literature on the combined use of cataract surgery (or lensectomy) and vitrectomy in pediatric patients, with a focus on clinical indications, surgical techniques, outcomes, and complications across various pediatric ocular pathologies. Methods: A narrative review of published studies addressing the use of combined lensectomy and vitrectomy (LV) in pediatric patients was conducted. Conditions discussed include congenital cataracts, ectopia lentis, retinopathy of prematurity (ROP), retinal detachment (RD), and persistent fetal vasculature (PFV). Key surgical considerations, visual and anatomical outcomes, and postoperative complications were examined. Results: The literature search yielded a total of 160 articles, of which 43 met the inclusion criteria and were included in this review. Although lens-sparing vitrectomy (LSV) is preferred in many pediatric cases to preserve accommodation and reduce complications, combined LV is often necessary in advanced or complex diseases. Studies have shown that combined LV can achieve favorable anatomical outcomes, but functional visual recovery remains variable and is affected by factors such as patient age, baseline ocular anatomy, and disease severity. Postoperative complications such as glaucoma, visual axis opacification (VAO), and intraocular lens (IOL) dislocation are more frequent with combined procedures and require long-term follow-up and rehabilitation. Conclusions: Combined cataract surgery (or lensectomy) and vitrectomy may represent a valuable strategy in the management of complex pediatric ocular conditions, particularly when individualized to the clinical context. Tailored surgical approaches are essential to optimize anatomic and functional outcomes. Further prospective studies and harmonized multicenter registries are needed to develop evidence-based principles that can guide individualized surgical decision-making in this unique patient population.
Open AccessCombined Cataract and Vitrectomy Surgery in Pediatric Patients
Purpose: To review the current literature on the combined use of cataract surgery (or lensectomy) and vitrectomy in pediatric patients, with a focus on clinical indications, surgical techniques, outcomes, and complications across various pediatric ocular pathologies. Methods: A narrative review of published studies addressing the use of combined lensectomy and vitrectomy (LV) in pediatric patients was conducted. Conditions discussed include congenital cataracts, ectopia lentis, retinopathy of prematurity (ROP), retinal detachment (RD), and persistent fetal vasculature (PFV). Key surgical considerations, visual and anatomical outcomes, and postoperative complications were examined. Results: The literature search yielded a total of 160 articles, of which 43 met the inclusion criteria and were included in this review. Although lens-sparing vitrectomy (LSV) is preferred in many pediatric cases to preserve accommodation and reduce complications, combined LV is often necessary in advanced or complex diseases. Studies have shown that combined LV can achieve favorable anatomical outcomes, but functional visual recovery remains variable and is affected by factors such as patient age, baseline ocular anatomy, and disease severity. Postoperative complications such as glaucoma, visual axis opacification (VAO), and intraocular lens (IOL) dislocation are more frequent with combined procedures and require long-term follow-up and rehabilitation. Conclusions: Combined cataract surgery (or lensectomy) and vitrectomy may represent a valuable strategy in the management of complex pediatric ocular conditions, particularly when individualized to the clinical context. Tailored surgical approaches are essential to optimize anatomic and functional outcomes. Further prospective studies and harmonized multicenter registries are needed to develop evidence-based principles that can guide individualized surgical decision-making in this unique patient population.
- 25 April 2025
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 9 (4) , 474-478
Early Treatment in Patients With Small and Medium-Small Class 2 Gene Expression Profiling Uveal Melanoma to Reduce Mortality
Purpose: To evaluate the class 2 gene expression profiling of patients with small and medium-small uveal melanoma, focusing on tumor control, metastases, and mortality. Methods: This retrospective case series evaluated patients treated for small or medium-small uveal melanoma by the same surgeon. Patients with small uveal melanoma were treated with microincision vitrectomy surgery or brachytherapy, and patients with medium-small uveal melanoma were treated with brachytherapy. All patients were gene expression profiling class 2. Results: Forty-two patients (21 with a diagnosis of small melanoma; 21 with a diagnosis of medium-small melanoma) with a mean age of 58 years and a confirmed diagnosis of class 2 gene expression profiling melanoma were identified. The melanoma-specific mortality at the 5-year follow-up was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. The rate of melanoma-specific active metastasis at 5 years was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. In both groups, the enucleation rate at 5 years was 0%. Conclusions: Small tumor management achieves excellent anatomic and visual outcomes but mandates diagnostic accuracy and defined long-term outcomes as well as follow-up (5-year minimum in this series). Gene expression profiling classification is important in prognostication; however, early treatment of small tumors significantly decreases the predicted mortality and has the greatest potential effect on patient survival, even for class 2 melanomas.
- 25 April 2025
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 9 (4) , 474-478
Early Treatment in Patients With Small and Medium-Small Class 2 Gene Expression Profiling Uveal Melanoma to Reduce Mortality
Purpose: To evaluate the class 2 gene expression profiling of patients with small and medium-small uveal melanoma, focusing on tumor control, metastases, and mortality. Methods: This retrospective case series evaluated patients treated for small or medium-small uveal melanoma by the same surgeon. Patients with small uveal melanoma were treated with microincision vitrectomy surgery or brachytherapy, and patients with medium-small uveal melanoma were treated with brachytherapy. All patients were gene expression profiling class 2. Results: Forty-two patients (21 with a diagnosis of small melanoma; 21 with a diagnosis of medium-small melanoma) with a mean age of 58 years and a confirmed diagnosis of class 2 gene expression profiling melanoma were identified. The melanoma-specific mortality at the 5-year follow-up was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. The rate of melanoma-specific active metastasis at 5 years was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. In both groups, the enucleation rate at 5 years was 0%. Conclusions: Small tumor management achieves excellent anatomic and visual outcomes but mandates diagnostic accuracy and defined long-term outcomes as well as follow-up (5-year minimum in this series). Gene expression profiling classification is important in prognostication; however, early treatment of small tumors significantly decreases the predicted mortality and has the greatest potential effect on patient survival, even for class 2 melanomas.
- 15 April 2025
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 9 (4) , 401-405
Peer-Review Essentials: Reviewing Manuscripts for the Journal of VitreoRetinal Diseases
The thoughtful process of peer review allows for the vetting and improvement of scientific work that leads to quality research and, eventually, advancement of the field of retina. Progress in medicine would not occur without dedicated researchers, but just as important are the peer reviewers who take the time assess their work, weigh in on their validity, and help bring these papers to life. Here, we discuss how to effectively review a journal manuscript in a way that helps both the beginning reviewer and the seasoned expert develop a framework to provide meaningful peer review. Although this guide was specifically written with JVRD aims in mind, these suggestions can be broadly applied to the process of manuscript review in general.
- 15 April 2025
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 9 (4) , 401-405
Peer-Review Essentials: Reviewing Manuscripts for the Journal of VitreoRetinal Diseases
The thoughtful process of peer review allows for the vetting and improvement of scientific work that leads to quality research and, eventually, advancement of the field of retina. Progress in medicine would not occur without dedicated researchers, but just as important are the peer reviewers who take the time assess their work, weigh in on their validity, and help bring these papers to life. Here, we discuss how to effectively review a journal manuscript in a way that helps both the beginning reviewer and the seasoned expert develop a framework to provide meaningful peer review. Although this guide was specifically written with JVRD aims in mind, these suggestions can be broadly applied to the process of manuscript review in general.
- 28 November 2024
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 9 (2) , 187-191
Targeted Multimodality Treatment to Eliminate the Need for Enucleation in Advanced Coats Disease
Purpose: To examine the trends and outcomes in the management of Coats disease and evaluate the effects of a staged therapeutic approach using transpupillary laser vascular ablation, intravitreal (IVT) bevacizumab, and adjunct as-needed posterior sub-Tenon triamcinolone acetonide (used only in cases with a persistent active exudation) on globe retention, anatomic status, and visual acuity (VA). Methods: An evaluation was performed from 2005 to 2023. Previous case series published in the literature were reviewed. In total, the case series comprised 68 patients who were evaluated and treated. In addition, a retrospective consecutive chart review was performed of novel cases of children with advanced Coats disease (stage 3 and 4) who were treated with targeted laser ablation coupled with IVT bevacizumab injection and supplemented with as-needed posterior sub-Tenon triamcinolone acetonide. Results: All patients had total resolution of the retinal detachment, and no patient had evidence of neovascular glaucoma after treatment. At 24 months, 11 (42%) of 26 eyes had better than 20/50 VA, 10 (39%) of 26 eyes had better than 20/400 VA, and 5 (19%) of 26 eyes had better than 5/200 VA. No eye required enucleation or developed endophthalmitis or inflammation after therapy with IVT bevacizumab. In addition, no case required incisional surgery. Conclusions: Treatment trends for advanced Coats disease have evolved, leading to enhanced patient outcomes and improved quality of life. Combined treatment with IVT bevacizumab, transpupillary laser vascular ablation, and as-needed posterior sub-Tenon triamcinolone acetonide results in improved anatomic outcomes.
- 28 November 2024
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 9 (2) , 187-191
Targeted Multimodality Treatment to Eliminate the Need for Enucleation in Advanced Coats Disease
Purpose: To examine the trends and outcomes in the management of Coats disease and evaluate the effects of a staged therapeutic approach using transpupillary laser vascular ablation, intravitreal (IVT) bevacizumab, and adjunct as-needed posterior sub-Tenon triamcinolone acetonide (used only in cases with a persistent active exudation) on globe retention, anatomic status, and visual acuity (VA). Methods: An evaluation was performed from 2005 to 2023. Previous case series published in the literature were reviewed. In total, the case series comprised 68 patients who were evaluated and treated. In addition, a retrospective consecutive chart review was performed of novel cases of children with advanced Coats disease (stage 3 and 4) who were treated with targeted laser ablation coupled with IVT bevacizumab injection and supplemented with as-needed posterior sub-Tenon triamcinolone acetonide. Results: All patients had total resolution of the retinal detachment, and no patient had evidence of neovascular glaucoma after treatment. At 24 months, 11 (42%) of 26 eyes had better than 20/50 VA, 10 (39%) of 26 eyes had better than 20/400 VA, and 5 (19%) of 26 eyes had better than 5/200 VA. No eye required enucleation or developed endophthalmitis or inflammation after therapy with IVT bevacizumab. In addition, no case required incisional surgery. Conclusions: Treatment trends for advanced Coats disease have evolved, leading to enhanced patient outcomes and improved quality of life. Combined treatment with IVT bevacizumab, transpupillary laser vascular ablation, and as-needed posterior sub-Tenon triamcinolone acetonide results in improved anatomic outcomes.
- 22 January 2024
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 8 (2) , 200-202
Long-Term Stability of Melanocytomas With Persistent Vascular Activity Without Malignant Transformation
Purpose: To present 2 cases of large atypical melanocytomas that simulate melanoma. Methods: The largest risk factors for malignant transformation from melanocytoma into malignant melanoma are a combination of lesions with a thickness greater than 2 mm, visual symptoms, and tumor margin at the disc. The patients in this report were chosen because they both presented these factors with their lesions. Results: Because the lesions were properly identified as melanocytomas of the optic disc, the decision was made to monitor them closely and treat the associated vascular activity. Ultrasounds and close observations are key in differentiating these benign lesions from malignant melanomas. Conclusions: Both patients experienced long-term stability with intravitreal injections when needed for vascular activity.
- 22 January 2024
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 8 (2) , 200-202
Long-Term Stability of Melanocytomas With Persistent Vascular Activity Without Malignant Transformation
Purpose: To present 2 cases of large atypical melanocytomas that simulate melanoma. Methods: The largest risk factors for malignant transformation from melanocytoma into malignant melanoma are a combination of lesions with a thickness greater than 2 mm, visual symptoms, and tumor margin at the disc. The patients in this report were chosen because they both presented these factors with their lesions. Results: Because the lesions were properly identified as melanocytomas of the optic disc, the decision was made to monitor them closely and treat the associated vascular activity. Ultrasounds and close observations are key in differentiating these benign lesions from malignant melanomas. Conclusions: Both patients experienced long-term stability with intravitreal injections when needed for vascular activity.
- 1 December 2023
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 8 (1) , 93-96
Gene Expression Profile Class Change in a Case of Aggressive, Recurrent Melanoma
Purpose: To report a novel case of a recurrent melanoma that had a change in its genetic expression profile (GEP) class over a 2-year period. Methods: This retrospective case study evaluated a patient with a recurrent uveal melanoma that changed classes from 1A to 1B. Results: A large melanoma was first treated with brachytherapy, and during that time genetic testing revealed a class 1A tumor. Two years later the tumor was noted to be enlarging, and the patient elected for enucleation. Subsequent GEP showed a class 1B tumor. Conclusions: An aggressive and large recurrent uveal melanoma that had changed from a class 1A to a class 1B tumor on subsequent GEP testing has never been reported before to our knowledge. It may imply that a recurrent or aggressive tumor has more mutations over time that could lead to a higher risk for metastasis. The natural course of a tumor’s GEP class should be explored further.
- 1 December 2023
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 8 (1) , 93-96
Gene Expression Profile Class Change in a Case of Aggressive, Recurrent Melanoma
Purpose: To report a novel case of a recurrent melanoma that had a change in its genetic expression profile (GEP) class over a 2-year period. Methods: This retrospective case study evaluated a patient with a recurrent uveal melanoma that changed classes from 1A to 1B. Results: A large melanoma was first treated with brachytherapy, and during that time genetic testing revealed a class 1A tumor. Two years later the tumor was noted to be enlarging, and the patient elected for enucleation. Subsequent GEP showed a class 1B tumor. Conclusions: An aggressive and large recurrent uveal melanoma that had changed from a class 1A to a class 1B tumor on subsequent GEP testing has never been reported before to our knowledge. It may imply that a recurrent or aggressive tumor has more mutations over time that could lead to a higher risk for metastasis. The natural course of a tumor’s GEP class should be explored further.
- 17 June 2023
- Published by Springer Nature
- p. 987-996
Management of Combined Hamartoma of the Retina and Retinal Pigment Epithelium in Children
- 17 June 2023
- Published by Springer Nature
- p. 987-996
Management of Combined Hamartoma of the Retina and Retinal Pigment Epithelium in Children